Management of Borderline Resectable Pancreatic Cancer

Department of Surgery, Medical College of Wisconsin, 9200 West Wisconsin Avenue, Milwaukee, WI 53226, USA. <>
Surgical Oncology Clinics of North America (Impact Factor: 1.81). 04/2010; 19(2):359-70. DOI: 10.1016/j.soc.2009.11.006
Source: PubMed


Borderline resectable pancreatic cancer is an emerging stage of disease defined by computed tomogrpahy criteria, patient (Katz type B), or disease characteristics (Katz type C). These patients are particularly well suited to a surgery-last strategy with induction therapy consisting of chemotherapy (gemcitabine alone or in combination) followed by chemoradiation. With appropriate selection and preoperative planning, many patients with borderline resectable disease derive clinical benefit from multimodality therapy. The use of a standardized system for the staging of localized pancreatic cancer avoids indecision and allows for the optimal treatment of all patients guided by the extent of their disease. In this article, 2 case reports are presented, and the term borderline resectable pancreatic cancer is discussed. The advantages of neoadjuvant therapy and surgery are also discussed.

1 Follower
4 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Evaluation of: Neoptolemos JP, Stocken DD, Bassi C et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs. gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 304(10), 1073-1081 (2010). Over the last decade, adjuvant therapy in the treatment of resected pancreas adenocarcinoma has had its value established. Such treatment incrementally increases 5-year survivorship and delays time to tumor recurrence. The backbone of adjuvant therapy is the single-agent gemcitabine, based primarily on results from the Charité Onkologie Clinical (CONKO)-001 study. Based on the combined results of the European Study Group for Pancreas Cancer (ESPAC)-1 and ESPAC-3 trials, Neoptolemos and colleagues have established both bolus 5-fluorouracil and leucovorin and gemcitabine as standard options for resected pancreatic cancer. Gemcitabine remains the main standard therapy based on its ease of administration and a more favorable toxicity profile; however, there is now a clearly validated alternate option of 5-fluororuacil and leucovorin based on the results of ESPAC-3. Moving forward, the integration of novel cytotoxic and targeted agents into adjuvant therapy, along with refining the role of neoadjuvant therapy for patients with resectable pancreas cancer, will hopefully accrue a more substantial improvement in outcome for patients with resected pancreas adenocarcinoma.
    Expert Review of Anti-infective Therapy 02/2011; 11(2):173-7. DOI:10.1586/era.10.232 · 2.25 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Although a variety of imaging techniques, such as multidetector computed tomography (MDCT), magnetic resonance imaging (MRI), endoscopic ultrasound, and fluorodeoxyglucose positron emission tomography have all been used in the initial diagnostic assessment of pancreatic lesions, in general, MDCT is the mainstay of diagnosis. This is due in large part to the high spatial resolution of its three-dimensional data sets that are indispensable in determining the local extent of tumor infiltration. This article describes MRI and MDCT techniques and accuracy and new horizons in MDCT in imaging of pancreatic cancer.
    Gastroenterology clinics of North America 03/2012; 41(1):159-77. DOI:10.1016/j.gtc.2011.12.012 · 2.82 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Trials examining FOLFIRINOX in metastatic pancreatic cancer demonstrate higher response rates compared to gemcitabine-based regimens. There is currently limited experience with neoadjuvant FOLFIRINOX in pancreatic cancer. Retrospective review of outcomes of patients with borderline resectable or locally unresectable pancreatic cancer who were recommended to undergo neoadjuvant treatment with FOLFIRINOX. FOLFIRINOX was recommended for 25 patients with pancreatic cancer, 13 (52%) unresectable and 12 (48%) borderline resectable. Four patients (16%) refused treatment or were lost to follow-up. Twenty-one patients (84%) were treated with a median of 4.7 cycles. Six patients (29%) required dose reductions secondary to toxicity. Two patients (9%) were unable to tolerate treatment and three patients (14%) had disease progression on treatment. Seven patients (33%) underwent surgical resection following treatment with FOLFIRINOX alone, 2 (10%) of which were initially unresectable. Two patients underwent resection following FOLFIRINOX + stereotactic body radiation therapy (SBRT). The R0 resection rate for patients treated with FOLFIRINOX ± SBRT was 33% (55% borderline resectable, 10% unresectable). A total of five patients (24%) demonstrated a significant pathologic response. FOLFIRINOX is a biologically active regimen in borderline resectable and locally unresectable pancreatic cancer with encouraging R0 resection and pathologic response rates. J. Surg. Oncol. 2013 108:236-241. © 2013 Wiley Periodicals, Inc.
    Journal of Surgical Oncology 09/2013; 108(4):236-41. DOI:10.1002/jso.23392 · 3.24 Impact Factor
Show more